These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10696236)

  • 1. Inhibition of solid tumor growth by Fas ligand-expressing myoblasts.
    Springer ML; Kraft PE; Blau HM
    Somat Cell Mol Genet; 1998 Sep; 24(5):281-9. PubMed ID: 10696236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Death of solid tumor cells induced by Fas ligand expressing primary myoblasts.
    Hofmann A; Blau HM
    Somat Cell Mol Genet; 1997 Jul; 23(4):249-57. PubMed ID: 9542527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
    Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
    J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutting edge: a novel role for Fas ligand in facilitating antigen acquisition by dendritic cells.
    Tada Y; O-Wang J; Takiguchi Y; Tatsumi K; Kuriyama T; Okada S; Tokuhisa T; Sakiyama S; Tagawa M
    J Immunol; 2002 Sep; 169(5):2241-5. PubMed ID: 12193688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege.
    Gregory MS; Repp AC; Holhbaum AM; Saff RR; Marshak-Rothstein A; Ksander BR
    J Immunol; 2002 Sep; 169(5):2727-35. PubMed ID: 12193747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth of FasL-bearing tumor cells in syngeneic murine host induces apoptosis and toxicity in Fas(+) organs.
    Zeytun A; Nagarkatti M; Nagarkatti PS
    Blood; 2000 Mar; 95(6):2111-7. PubMed ID: 10706882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fulminant hepatitis by Fas-ligand expression in MRL-lpr/lpr mice grafted with Fas-positive livers and wild-type mice with Fas-mutant livers.
    Li XK; Fujino M; Sugioka A; Morita M; Okuyama T; Guo L; Funeshima N; Kimura H; Enosawa S; Amemiya H; Suzuki S
    Transplantation; 2001 Feb; 71(4):503-8. PubMed ID: 11258428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
    Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
    J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects are produced by forced expression of membrane-bound but not soluble Fas ligand in murine lung carcinoma cells.
    Tada Y; O-Wang J; Seimiya M; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
    Anticancer Res; 2002; 22(2A):831-6. PubMed ID: 12014659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors.
    Hohlbaum AM; Gregory MS; Ju ST; Marshak-Rothstein A
    J Immunol; 2001 Dec; 167(11):6217-24. PubMed ID: 11714783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fas ligand-transfected myoblasts and islet cell transplantation.
    Turvey SE; Gonzalez-Nicolini V; Kingsley CI; Larregina AT; Morris PJ; Castro MG; Lowenstein PR; Wood KJ
    Transplantation; 2000 May; 69(9):1972-6. PubMed ID: 10830245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fas ligand on tumor cells mediates inactivation of neutrophils.
    Chen YL; Chen SH; Wang JY; Yang BC
    J Immunol; 2003 Aug; 171(3):1183-91. PubMed ID: 12874204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice.
    Lau HT; Yu M; Fontana A; Stoeckert CJ
    Science; 1996 Jul; 273(5271):109-12. PubMed ID: 8658177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct in vivo transfection of antisense Fas-ligand reduces tumor growth and invasion.
    Nyhus JK; Wolford C; Feng L; Barbera-Guillem E
    Gene Ther; 2001 Feb; 8(3):209-14. PubMed ID: 11313792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fas/Apo-1 (CD95)-mediated apoptosis of neutrophils with Fas ligand (CD95L)-expressing tumors is crucial for induction of inflammation by neutrophilic polymorphonuclear leukocytes associated with antitumor immunity.
    Shimizu M; Fontana A; Takeda Y; Yoshimoto T; Tsubura A; Matsuzawa A
    Cell Immunol; 2001 Jan; 207(1):41-8. PubMed ID: 11161452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression.
    Delgado M; Ganea D
    J Immunol; 2000 Jul; 165(1):114-23. PubMed ID: 10861043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of autoimmune diabetes by Fas ligand: the paradox is solved.
    Kim S; Kim KA; Hwang DY; Lee TH; Kayagaki N; Yagita H; Lee MS
    J Immunol; 2000 Mar; 164(6):2931-6. PubMed ID: 10706679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fas-mediated cytotoxicity is not required for rejection of murine nonvascularized heterotopic cardiac allografts.
    Djamali A; Odorico JS
    Transplantation; 1998 Dec; 66(12):1793-801. PubMed ID: 9884278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 promotes selection for Fas-mediated apoptotic resistance.
    Maecker HL; Koumenis C; Giaccia AJ
    Cancer Res; 2000 Aug; 60(16):4638-44. PubMed ID: 10969818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival.
    Min WP; Gorczynski R; Huang XY; Kushida M; Kim P; Obataki M; Lei J; Suri RM; Cattral MS
    J Immunol; 2000 Jan; 164(1):161-7. PubMed ID: 10605007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.